PressJuly 1, 2024 Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
PressJune 27, 2024 MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001
PressJune 27, 2024 Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists
PressJune 26, 2024 atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
PressJune 25, 2024 Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
PressJune 25, 2024 Health Canada Issues Three Export Permits to Optimi to Supply Patients Under Australia’s Authorised Prescriber Scheme
PressJune 24, 2024 Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium Production
Health & ScienceJune 21, 2024 What Mindbloom’s Ketamine Study Could Mean for the Psychedelics Industry
PressJune 20, 2024 MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
PressJune 20, 2024 Atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
PressJune 20, 2024 Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
PressJune 19, 2024 Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
PressJune 19, 2024 Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Health & ScienceJune 14, 2024 UC Berkeley’s Groundbreaking Study Exploring Psilocybin’s Effects on Perception
